Aprogen Biologics (003060) Stock Statistics & Valuation Metrics

Aprogen Biologics has a market cap or net worth of ₩27.77B. The enterprise value is ―.

Aprogen Biologics has 14,412,374 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aprogen Biologics’s return on equity (ROE) is -0.82 and return on invested capital (ROIC) is -23.13%.

The current PE Ratio of Aprogen Biologics is ―. Aprogen Biologics’s PEG ratio is -0.00969.

In the last 12 months, Aprogen Biologics had revenue of 73.23B and earned -170.33B in profits. Earnings per share was -12.92K.

In the last 12 months, operating cash flow was -36.25B and capital expenditures -5.57B, giving a free cash flow of -41.83B billion.

Aprogen Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

Aprogen Biologics upcoming earnings date is Aug 19, 2026, TBA (Confirmed).

Aprogen Biologics as a current ratio of 0.67, with Debt / Equity ratio of 111.52%

In the past 12 months, Aprogen Biologics has paid -1.08B in taxes.

Aprogen Biologics EV to EBITDA ratio is -2.93, with an EV/FCF ratio of -6.35.

Aprogen Biologics has ₩50.10B in cash and marketable securities with ₩227.15B in debt, giving a net cash position of -₩177.05B billion.

Gross margin is -30.80%, with operating margin of -167.82%, and net profit margin of -232.61%.

The average price target for Aprogen Biologics is ―, which is 11.43% higher than the current price. The consensus rating is ―